Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone

OBJECTIVE: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels. METHODS: From January 2017 to January 2020, 80 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xirui, Hu, Changwei, Li, Yabin, Ren, Baowen, Yin, Gangfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959954/
https://www.ncbi.nlm.nih.gov/pubmed/35356252
http://dx.doi.org/10.1155/2022/8361775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959954/
https://www.ncbi.nlm.nih.gov/pubmed/35356252
http://dx.doi.org/10.1155/2022/8361775

Ejemplares similares